The pathogenesis of cardiac allograft vasculopathy

Current Opinion in Cardiology

Volumn 11, Issue 2, 1996, Pages 183-190

  Dong, Chunming ^a   Redenbach, Darlene ^a   Wood, Shelley ^a   Battistini, Bruno ^a   Wilson, Janet E ^a   McManus, Bruce M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; ENDOTHELIN; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; LIPOPROTEIN; PROTEOGLYCAN; RAPAMYCIN; TACROLIMUS;

ALLOGRAFT; CELL DEATH; CELL PROLIFERATION; CYTOMEGALOVIRUS INFECTION; DYSLIPIDEMIA; ECHOGRAPHY; ENDOTHELIUM CELL; HEART TRANSPLANTATION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE;

ANIMALS; CELL DEATH; CELL DIVISION; CORONARY DISEASE; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029881421     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199603000-00012     Document Type: Review

References (54)

1. Billingham ME: Cardiac transplant atherosclerosis. Transplant Proc 1987, 19(4 suppl 5):19-25.
2. Gao SZ, Schroeder JS, Alderman EL, Hunt SA, Silverman JF: Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 1987, 76(suppl V):V-56-V-61.
3. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA: Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988, 12:334-340.
4. Pahl E, Zales VR, Fricker J, Addonizio LJ: Posttransplant coronary artery disease in children: a multicenter national survey. Circulation 1994, 90(part 2):II-56-II-60.
5. Mehra MR, Ventura HO, Smart FW, Collins TJ, Ramee SR, Stapleton DD: An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol 1995, 75:853-854.
6. Barbir M, Bowker T, Ludman PF, Mitchell AG, Wood D, Yacoub M: Ultrafast computed tomographic scanning for detection of coronary disease in cardiac transplant recipients. Am J Cardiol 1994, 74:941-944.
7. Akosah KO, Mohanty PK, Funai JT, Jesse RL, Minisi AJ, Crandall CW, Kirchberg D, Guerraty A, Salter D: Noninvasive detection of transplant coronary artery disease by dobutamine stress echocardiography. J Heart Lung Transplant 1994, 13:1024-1038.
8. Lin H, Wilson JE, Kendall TJ, Rardio SJ, Cornhill FJ, Herderick E, Winters GL, Costanso MR, Porter T, Thieszen SL, McManus BM: Comparable proximal and distal severity of intimal thickening and size of epicardial coronary arteries in transplant arteriopathy of human cardiac allografts. J Heart Lung Transplant 1994, 13:824-833. Describes in great detail the distinct morphology of CAV, which involves the comparable severity of intimal thickening of proximal and distal epicardial coronary arteries in human cardiac aloografts using autopsy tissues.
9. Ross R: Atherosclerosis: current understanding of mechanisms and future strategies in therapy [review]. Transplant Proc 1993, 25:2041-2043.
10. Clinton SK, Libby P: Cytokines and growth factors in atherogenesis [review]. Arch Pathol Lab Med 1992, 116:1292-1300.
11. Libby P, Warner SJC, Solomon RN : Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N Engl J Med 1988, 318:1493-1498.
12. Casscells W, Lappi DA, Olwin BB, Wai C, Siegman M, Speir EH, Sasse J, Baird A: Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc Natl Acad Sci U S A 1992, 89:7159-7163.
13. Zhao XM, Yeoh TK, Hiebert M, Frist H, Miller GG: The expression of acidic fibroblast growth factor (heparin binding growth 1) and cytokine genes in human cardiac allografts and T cells. Transplantation 1993, 56:1177-1182.
14. Zhao XM, Frist WH, Yeoh TK, Miller GG : Expression of cytokine genes in human cardiac allografts correlation of IL-6 and TGF-beta with histological rejection. Clin Exp Immunol 1993, 93:448-451.
15. Russell ME, Utans U, Wallace A, Liang P, Arceci RJ, Karnovsky MJ, Wyner LR, Yamashita Y, Tarn C: Identification and upregulation of galactose/N-acetylgalactosamine macrophage lectin in rat cardiac allografts with arteriosclerosis. J Clin Invest 1994, 194:722-730.
16. Cramer DV, Wu GD, Chapman FA, Cajulis E, Wang HK, Makowka L: Lymphocytic subsets and histopathologic changes associated with the development of heart transplant arteriosclerosis. J Heart Lung Transplant 1992, 11:458-466.
17. Adams DH, Wyner LR, Karnovsky MJ: Experimental graft arteriosclerosis: Part II. Immunocytochemical analysis of lesion development. Transplantation 1993, 56:794-799.
18. Hayry P, Alatalo S, Myllarniemi M, Raisanen-Sololowski A, Lemstrom K: Cellular and molecular biology of chronic rejection. Transplant Proc 1995, 27:71-74.
19. Zhao XM, Frist WH, Yeoh TK, Miller GG: Modification of alternative messenger RNA splicing of fibroblast growth factor receptors in human cardiac allografts during rejection. J Clin Invest 1994, 94:992-1003. Describes in detail the expression of messenger RNA encoding different domains of aFG receptors in cardiac allograft rejection, the relationship of this expression with cytokines, and the potential role of this expression in CAV.
20. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P: Growth regulatory properties of endothelins. Peptides 1992, 14:385-399.
21. Dubin D, Pratt RE, Cooke JP, Dzau VJ: Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vasc Med Biol 1989, 1:150-154.
22. Gibbons gh, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med 1994, 330:1431-1438.
23. Watschinger B, Sayegh MH, Hancock WW, Russell ME: Up-regulation of endothelin-1 mRNA and peptide expression in rat cardiac allografts with rejection and arteriosclerosis. Am J Pathol 1995, 146:1065-1072.
24. Berkenboom G, Giot C, Unger P, Vachiery JL, Antoine M, LeClerc JL: Plasma endothelin and early coronary endothelial dysfunction in recipients of a cardiac transplant. Am Heart J 1994, 129:1178-1184.
25. Sudhir K, DeMarco T, Kumar S, Maganti K, Amidon TM, de Groot, CJM, Klinski C, Lau D, Keith F, TaylorRN, Chatterjee K: Transcoronary and pulmonary vascular dynamics of endothelin-1 in heart transplant recipients. J Heart Lung Transplant 1995, 14:230-235.
26. Aptecar E, Benvenuti C, Loisance D, Cachera JP, Nitenberg A: Early impairment of acetylcholine-induced endothelium-dependent coronary vasodilation is not predictive of secondary graft atherosclerosis. Chest 1995, 107:1266-1274.
27. Fullerton DA, Mitchell MB, McIntyre Jr RC, Brown JM, Meng X, Campbell DN, Grover FL: Mechanisms of coronary vasomotor dysfunction in the transplanted heart. Ann Thorac Surg 1994, 58:86-92.
28. Deng MC, Bell S, Huie P, Pinto F, Hunt SA, Stinson EB, Sibley R, Hall BM, Valantine HA: Cardiac allograft vascular disease: relationship to microvascular cell surface markers and inflammatory cell phenotypes on endomyocardial biopsy. Circulation 1995, 91:1647-1654.
29. Jutte NHPM, Groeneveld K, Balk AHMM, Ouwehand AJ, Loonen EHM, Van der Linden M, Strikwerda S, Mochtar B, Claas FHJ, Weimar W: The development of transplant coronary artery disease after cardiac transplantation is correlated with a predominance of CDS+ T lymphocytes in endomyocardial biopsy derived T cell cultures. Clin Exp Immunol 1994, 98:158-162.
30. Squier MKT, Cohen JJ: Cell-mediated cytotoxic mechanisms. Curr Opin Immunol 1994, 6:447-452.
31. Lowin B, Hahe M, Mattmann C, Tschopp J: Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 1994, 370:650-652. Clearly demonstrates that cytotoxicity imparted by cytolytic T cells is exclusively mediated by perform- and Fas-based lytic pathways by in vitro work.
32. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Goldstein P: Fas and perforin pathways as major mechanisms of T-cell-mediated cytotoxicity. Science 1994, 265:528-530. Clearly demonstrates that cytotoxicity imparted by cytolytic T cells is exclusively mediated by perforin- and Fas-based lytic pathways by in vitro work.
33. Dong C, Wilson JE, Winters GL, McManus BM: Human transplant coronary artery disease: pathological evidence for fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest 1996, in press. The first paper describing apoptosis and its pathway in transplantation CAV. The authors also describe the different form of cell death seen in native coronary artery disease and the potential relevance to the different morphology and development of transplantation coronary artery disease and native coronary artery disease.
34. Stalder T, Hahn S, Erb P: Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994, 152:1127-1133.
35. Raisanen-Sokolowski A, Tilly-Keisi T, Ustinov J, Mennander A, Paavonen T, Tikkanen MJ, Hayry P: Hyperlipidemia accelerates allograft arteriosclerosis (chronic rejection) in the rat. Arterioscler Thromb 1994, 14:2032-2042.
36. Ravalli S, Marboe CC, D'Agati VD, Michler RE, Sigal E, Cannon PJ: Immunohistochemical demonstration of 15-Lipoxygenase in transplant coronary artery disease. Arterioscler Thromb Vasc Biol 1995, 15:340-348.
37. Anguita M, Alonso-Pulpon L, Arizon JM, Cavero MA, Valles F, Segovia J, Perez-Jimenez,F Crespo M, Concha M: Comparison of the effectiveness of Lovastatin therapy for hypercholesterolemia after heart transplantation between patients with and without pretransplant atherosclerotic coronary artery disease. Am J Cardiol 1994, 74:776-779.
38. McManus BM, Horley KJ, Wilson JE, Malcolm GT, Kendall TJ, Miles RR, Winters GL, Costanzo MR, Miller LL, Radio SJ: Prominence of coronary arterial wall lipids in human heart allografts. Am J Pathol 1995, 147:1-16. This elegant paper reveals significant lipid deposition in the coronary artery walls of patients with CAV.
39. Lin H, Wilson JE, Roberts CR, Horley KJ, Winter GL, Costanzo MR, McManus BM: Biglycan, decorin and versican protein expression patterns in coronary arteriopathy of human heart allografts: distinctness as compared to native atherosclerosis. J Heart Lung Transplant 1995, in press. The first paper to describe biglycan, decorin, and versican expression using immunohistochemistry in CAV and native atherosclerosis as well as in normal coronary arteries.
40. Lin H, Ignatescu M, Wilson JE, Roberts CR, Horley KJ, Winters GL, Costanzo MR, McManus BM: Prominence of apolipoproteins B, (a) and E in the intimae of coronary arteries in transplanted human hearts: geographical relationship to vessel wall proteoglycans. J Heart Lung Transplant 1995, in press. Details distribution of apoplipoproteins in CAV and the relationship of CAV with proteoglycans. The authors also discuss the potential role of apolipoproteins in CAV.
41. Linton MF, Atkinson JB, Fazio S: Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995, 267:1034-1037. This meticulous work, using apolipoprotein E-deficient mice, clearly demonstrates that apolipoprotein E can prevent atherosclerosis.
42. Speir E, Modali R, Huang E-S, Leon MB, Shawl F, Finkel T, Epstein SE: Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994, 265:391-394. Demonstrates for the first time that tumor supressor gene p53 and human cytomegalovirus are linked to coronary restenosis.
43. McDonald K, Rector TS, Braunlin EA, Kubo SH, Olivari MT: Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol 1989, 64:359-362.
44. Lemstrom KB, Aho PT, Bruggeman CA, Hayry PJ: Cytomegalovirus infection enhances mRNA expression of platelet-derived growth factor-BB and transforming growth factor-B1 in rat aortic allografts: possible mechanism for cytomegalovirus-enhanced graft arteriosclerosis. Arterioscler Thromb 1994, 14:2043-2052.
45. Lemstrom KB, Bruning JH, Bruggeman CA, Koskinen PK, Aho PT, Yilmaz S, Lautenschlager IT, Hayry PJ: Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. Circulation 1994, 90:1969-1978.
46. Dummer S, Lee A, Breinig MK, Kormos R, Ho M, Griffith B: Investigation of cytomegalovirus infection as a risk factor for coronary atherosclerosis in the explanted hearts of patients undergoing heart transplantation. J Med Virol 1994, 44:305-309.
47. Gulizia JM, Kandolf R, Kendall TJ, Thieszan SL, Wilson JE, Radio SJ, Costanzo MR, Winters GL, Miller LL, McManus BM: Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts. Am J Pathol 1995, 147:461-475. This work convincingly demonstrates that cytomegalovirus genome is not frequent in CAV as compared with native atherosclerosis. Molecular techniques, including in situ hybridization and polymerase chain reaction, are used.
48. Nagamine S, Ohmi M, Tabayashi K, Iguchi A, Mohri H: Effects of cyclosporine and 15-deoxyspergualin on coronary arteriosclerosis after heart transplantation in the rat. J Heart Lung Transplant 1994, 13:895-898.
49. Hirozane T, Matsumon A, Furukawa Y, Sasayama S: Experimental graft coronary artery disease in murine heterotopic cardiac transplant model. Circulation 1995, 91:386-392.
50. Shi C, Russell ME, Bianchi C, Newell JB, Haber E: Murine model of accelerated transplant arteriosclerosis. Circ Res 1995, 75:199-207. Establishes a novel mutine model of CAV that facilitate the molecular study of human CAV.
51. Schowengerdt KO, Zhu JY, Stepkowski SM, Tu Y, Entman ML, Ballantyne CM: Cardiac allograft survival in mice deficient in intercellular adhesion molecule-1. Circulation 1995, 92:82-87.
52. Schmid C, Heemann U, Azuma H, Tilney NL: Comparison of rapamycin, RS 61443, cyclosporine, and low-dose heparin as treatment for transplant vasculopathy in a rat model of chronic allograft rejection. Transplant Proc 1995, 27:438-439.
53. Izutani H, Miyagawa S, Matsumiya G, Nakata S, Shimazaki Y, Matsuda H, Shirakura R: Graft coronary arteriosclerosis in rat heart transplant model with FK 506 short-term administration. Transplant Proc 1995, 27:579-581.
54. Nair RV, Morris RE: Immunosuppression in cardiac transplantation: a new era in immunopharmacology. Curr Opin Cardiol 1995, 10:207-217.